Clin Psychopharmacol Neurosci.  2018 Feb;16(1):32-38. 10.9758/cpn.2018.16.1.32.

Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics

• Pavăl D
• NemeÅŸ B
• Rusu RL
• Dronca E

• KMID: 2405231
• DOI: http://doi.org/10.9758/cpn.2018.16.1.32

Abstract

OBJECTIVE
Recent studies suggest a possible involvement of low paraoxonase 1 (PON1) enzyme activities in the association between schizophrenia, treatment with atypical antipsychotics and increased cardiovascular (CVD) risk. In the present study, we aimed at investigating the PON1 status in a group of schizophrenic patients treated with either olanzapine or other antipsychotic, as compared to a group of healthy control participants.
METHODS
We assessed the arylesterase (AREase) and paraoxonase (POase) activities of PON1, as well as three common polymorphisms of PON1 gene (Q192R, L55M, −108C>T).
RESULTS
We found significantly lower (−13.3%) AREase activity in schizophrenic patients, along with significantly lower (−18.2%) POase activity in olanzapine-treated patients with QQ genotype. Furthermore, we found a significant difference between groups in L55M polymorphism distribution, whereas Q192R and −108C>T polymorphisms distributions were similar.
CONCLUSION
We identified the olanzapine-treated patients with QQ genotype as having the lowest PON1 (POase) activity, providing a possible way of identifying schizophrenic patients exposed to the greatest risk of CVD.

Keyword

Paraoxonase 1; PON1; Polymorphism; Atypical antipsychotics; Olanzapine; Cardiovascular diseases

MeSH Terms

Antipsychotic Agents*
Aryldialkylphosphatase*
Cardiovascular Diseases
Genotype
Humans
Poa
Schizophrenia
Antipsychotic Agents
Aryldialkylphosphatase